Search filters

Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 89
  • 14
  • 169
  • 697
  • 454
  • 14
  • 32
  • 1
  • 4
  • 648

Found 699 none trials

A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

99 years or below
All genders
Phase 1
The primary objective of this study is to characterize the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) or maximum administered dose (MAD) (if no MTD is defined) of MGD013 when administered intravenously (IV) every 2 weeks to patients with unresectable, locally advanced or metastatic cancers.
99 years or below
All genders
Phase 1
This research study is being done to study a new way to possibly treat cystic fibrosis lung disease. The investigational drug to be tested in the present study is known by its code name MRT5005. MRT5005 consists of very small particles containing messenger ribonucleic acid (mRNA), which has the genetic …
 UPCC 15518 / ANAM-17-21: A Phase 3  Randomized  Double-Blind  Placebo-Controlled  Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
18 years - 99 years
All genders
Phase 3
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
99 years or below
All genders
Phase 4
This is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, exploratory Phase 4 study. The purpose is to identify the effect of selexipag on daily life physical activity assessed by a wearable device in patients with PAH (WHO Group 1). Approximately 100 patients will be enrolled in the study at 45 …
99 years or below
All genders
Phase 2
This research study is an open-label study designed to learn about the safety and effectiveness of an experimental drug called avapritinib (also known as BLU-285) when given to individuals who have been diagnosed with ASM, SM-AHN, or MCL. Experimental means that it is not yet known if this drug helps …
 Phase 1 Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells (CART22-65s) alone and when co-administered with humanized Anti-CD19 Chimeric Antigen Receptor Redirected T cells (huCART19) In Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
99 years or below
All genders
Phase 1
This is a single center, single arm, open-label Phase 1 study with two cohorts to determine the safety and feasibility of infusing CART22-65s with or without huCART19 after administration of lymphodepleting chemotherapy in adult patients with relapsed or refractory B-ALL.
 Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor alpha Redirected T Cells for Recurrent High Grade Serous Ovarian  Fallopian Tube  or Primary Peritoneal Cancer
99 years or below
All genders
Phase 1
This is a Phase I study evaluating the safety and feasibility of intraperitoneal administered lentiviral transduced MOv19-BBz CAR-T cells in 4 cohorts with or without cyclophosphamide + fludarabine in a 3+3 dose escalation design. Up to 18 evaluable subjects will be treated.
99 years or below
All genders
Phase 1
This is a Phase 1/2, open-label, multicenter dose-escalation and dose-expansion trial evaluating the safety and tolerability of fimepinostat administered orally to patients with R/R lymphoma.
99 years or below
All genders
Phase 1
The purposes of this study are to see if the study drugs, venetoclax and gilteritinib can be safely and effectively combined for the treatment of patients with acute myeloid leukemia (AML) that has returned after prior treatment, or has failed to respond to prior treatment and identify potential biomarkers.
99 years or below
All genders
Phase 2
The study will enroll cognitively unimpaired individuals who are between the ages of 60-75 years with at least one APOE4 allele (HMs or HTs) and, if HTs, with evidence of elevated brain amyloid. Cognitively unimpaired subjects defined as having a Mini-Mental State Examination (MMSE) total score greater than or equal …
611 - 620 of 699